Study on Enoxaparin and Chemotherapy for Pancreatic Cancer
Author Information
Author(s): Hanno Riess, Uwe Pelzer, Andreas Hilbig, Jens Stieler, Bernhard Opitz, Theo Scholten, Dörte Kauschat-Brüning, Peter Bramlage, Bernd Dörken, Helmut Oettle
Primary Institution: Charité Campus Virchow-Clinic, Medical Clinic Hematology/Oncology, Berlin, Germany
Hypothesis
Does the addition of enoxaparin to chemotherapy improve outcomes in patients with advanced pancreatic cancer?
Conclusion
The PROSPECT study aims to clarify the role of low molecular weight heparins in preventing venous thromboembolism and their impact on survival and remission rates in pancreatic cancer patients.
Supporting Evidence
- Pancreatic cancer has one of the highest rates of venous thromboembolic events compared to other cancers.
- Enoxaparin has been shown to be effective in preventing VTE in surgical and general medical patients.
- The study aims to analyze the efficacy of enoxaparin in patients undergoing systemic chemotherapy for pancreatic cancer.
Takeaway
This study is testing if a blood thinner called enoxaparin can help people with pancreatic cancer live longer and have fewer blood clots while they get chemotherapy.
Methodology
A multicenter, randomized, open-label phase IIb trial comparing enoxaparin treatment to no anticoagulation in patients receiving chemotherapy for pancreatic cancer.
Potential Biases
Potential bias in patient selection and reporting of outcomes.
Limitations
The study may not account for all variables affecting patient outcomes, and results may not be generalizable to all pancreatic cancer patients.
Participant Demographics
Patients with locally advanced or metastatic pancreatic cancer, aged 18 and older, with a Karnofsky performance status of 60% or higher.
Statistical Information
P-Value
0.0001
Statistical Significance
p<0.05
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website